TY - JOUR
T1 - Nanotechnological Strategies for Osteoarthritis Diagnosis, Monitoring, Clinical Management, and Regenerative Medicine
T2 - Recent Advances and Future Opportunities
AU - Mohammadinejad, Reza
AU - Ashrafizadeh, Milad
AU - Pardakhty, Abbas
AU - Uzieliene, Ilona
AU - Denkovskij, Jaroslav
AU - Bernotiene, Eiva
AU - Janssen, Lauriane
AU - Lorite, Gabriela S
AU - Saarakkala, Simo
AU - Mobasheri, Ali
N1 - Funding Information:
The research underpinning some of the work presented has received funding from a number of sources including The European Commission Framework 7 programme (EU FP7; HEALTH.2012.2.4.5-2, project number 305815; Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases) and the Innovative Medicines Initiative Joint Undertaking under grant agreement No. 115770, resources of which are composed of financial contribution from the European Union’s Seventh Framework programme (FP7/2007–2013), EFPIA companies’ in-kind contribution and the H2020 projects RESTORE (project number 814558; topic NMBP-22-2018 RIA), and MIRACLE (project number 780598; topic ICT-30-2017). Details of the D-BOARD FP7 Consortium are available at: http://www.d-board.eu . Details of the APPROACH IMI Consortium are available at https://www.approachproject.eu . Details of the H2020-RESTORE Consortium are available at restoreproject.eu. Details on the H2020-MIRACLE Consortium are available at miracleproject.eu. A.M. received funding from the European Commission through a Marie Curie Intra-European Fellowship for Career Development grant (project number 625746; acronym: CHONDRION; FP7-PEOPLE-2013-IEF) and financial support from the European Structural and Social Funds through the Research Council of Lithuania (Lietuvos Mokslo Taryba) according to the activity “Improvement of researchers” qualification by implementing world-class R&D projects” of Measure No. 09.3.3-LMT-K-712 (grant application code: 09.3.3-LMT-K-712-01-0157, agreement No. DOTSUT-215). A.M., E. B, I. U, and J. D also received financial support from the European Structural and Social Funds through the Research Council of Lithuania (Lietuvos Mokslo Taryba) according to the Programme “Attracting Foreign Researchers for Research Implementation,” Grant No. 0.2.2-LMT-K-718-02-0022. Acknowledgments
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/4/4
Y1 - 2020/4/4
N2 - Purpose of Review: In this review article, we discuss the potential for employing nanotechnological strategies for the diagnosis, monitoring, and clinical management of osteoarthritis (OA) and explore how nanotechnology is being integrated rapidly into regenerative medicine for OA and related osteoarticular disorders. Recent Findings: We review recent advances in this rapidly emerging field and discuss future opportunities for innovations in enhanced diagnosis, prognosis, and treatment of OA and other osteoarticular disorders, the smart delivery of drugs and biological agents, and the development of biomimetic regenerative platforms to support cell and gene therapies for arresting OA and promoting cartilage and bone repair. Summary: Nanotubes, magnetic nanoparticles, and other nanotechnology-based drug and gene delivery systems may be used for targeting molecular pathways and pathogenic mechanisms involved in OA development. Nanocomposites are also being explored as potential tools for promoting cartilage repair. Nanotechnology platforms may be combined with cell, gene, and biological therapies for the development of a new generation of future OA therapeutics. [Figure not available: see fulltext.]
AB - Purpose of Review: In this review article, we discuss the potential for employing nanotechnological strategies for the diagnosis, monitoring, and clinical management of osteoarthritis (OA) and explore how nanotechnology is being integrated rapidly into regenerative medicine for OA and related osteoarticular disorders. Recent Findings: We review recent advances in this rapidly emerging field and discuss future opportunities for innovations in enhanced diagnosis, prognosis, and treatment of OA and other osteoarticular disorders, the smart delivery of drugs and biological agents, and the development of biomimetic regenerative platforms to support cell and gene therapies for arresting OA and promoting cartilage and bone repair. Summary: Nanotubes, magnetic nanoparticles, and other nanotechnology-based drug and gene delivery systems may be used for targeting molecular pathways and pathogenic mechanisms involved in OA development. Nanocomposites are also being explored as potential tools for promoting cartilage repair. Nanotechnology platforms may be combined with cell, gene, and biological therapies for the development of a new generation of future OA therapeutics. [Figure not available: see fulltext.]
KW - Cartilage
KW - Diagnostic
KW - Nanotechnology
KW - Osteoarthritis
KW - Regenerative medicine
UR - https://www.scopus.com/pages/publications/85082974230
U2 - 10.1007/s11926-020-0884-z
DO - 10.1007/s11926-020-0884-z
M3 - Article
C2 - 32248371
SN - 1523-3774
VL - 22
SP - 1
EP - 17
JO - Current Rheumatology Reports
JF - Current Rheumatology Reports
IS - 4
M1 - 12
ER -